Systems approaches are needed to recognise the complexity of the biological bases of psychiatric disease
The bases of mental disorders can best be understood as a complex interplay between biological, psychological, social and lifestyle factors: a classic bio-psycho-social-lifestyle model. There are undoubtedly some disorders where a biological model alone is more appropriate — this applies particularly to the psychotic disorders — but even in such cases it must be acknowledged that these illnesses are strongly influenced by psychosocial and lifestyle factors. What makes a biological understanding of mental illnesses necessary, however, is that it opens the way for the development of rational treatments. This has been the quest since antiquity, with treatments predicated on the putative underlying biological causes: purging and bleeding patients to correct imbalances in the humours to treat melancholia, which was attributed to an excess of black bile, or removing sources of focal infection, such as the teeth, tonsils and even the colon, that were once regarded as causing mental disorders. While these models perhaps now seem far-fetched, they were not entirely implausible when one considers contemporary neuro-endocrine and neuro-inflammatory models of mental illness.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011; 12: 56-68.
- 2. Dash S, Clarke G, Berk M, Jacka FN. The gut microbiome and diet in psychiatry: focus on depression. Curr Opin Psychiatry 2015; 28: 1-6.
- 3. Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev 2014; 45: 46-62.
- 4. Anderson G, Berk M, Dean O, et al. Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs 2014; 28: 1-10.
- 5. Deepmala, Slattery J, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev 2015; 55: 294-321.
- 6. Boyce P, Hopwood M. Manipulating melatonin in managing mood. Acta Psychiatr Scand 2013; Suppl s444: 16-23.
- 7. Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature 2016; 530: 177-183.
- 8. Maes M, Scharpe S, Bosmans E, et al. Disturbances in acute phase plasma proteins during melancholia: additional evidence for the presence of an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 501-515.
- 9. Grover MP, Ballouz S, Mohanasundaram KA, et al. Identification of novel therapeutics for complex diseases from genome-wide association data. BMC Med Genomics 2014; 7 Suppl 1: S8.
- 10. Berk M, Nierenberg AA. Three paths to drug discovery in psychiatry. Am J Psychiatry 2015; 172: 412-414.
Michael Berk is supported by a National Health and Medical Research Council Senior Principal Research Fellowship (1059660).
No relevant disclosures.